Enlivex Therapeutics

$15.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.38 (+2.55%) As of 5:32 PM UTC today

Why Robinhood?

You can buy or sell ENLV and other stocks, options, and ETFs commission-free!

About ENLV

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel. The listed name for ENLV is Enlivex Therapeutics Ltd. Ordinary Shares.

CEO
Oren Hershkovitz
Employees
—
Headquarters
Nes-Ziona, Tel Aviv
Founded
—
Market Cap
251.65M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
637.18K
High Today
$15.88
Low Today
$15.02
Open Price
$15.88
Volume
185.74K
52 Week High
$29.40
52 Week Low
$3.59

ENLV Earnings

-$0.32
-$0.21
-$0.11
$0.00
Q1 FY17
Q2 FY17
Q3 FY17
Q4 FY17
Q1 FY18
Q2 FY18
Q3 FY18
Q4 FY18
Estimated
— per share
Actual
Available Apr 30, After Hours

You May Also Like

APOPW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure